While Neogenomics Inc has overperformed by 9.11%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NEO fell by -12.84%, with highs and lows ranging from $19.11 to $12.12, whereas the simple moving average fell by -9.15% in the last 200 days.
On January 13, 2025, The Benchmark Company Downgraded Neogenomics Inc (NASDAQ: NEO) to Hold. A report published by Jefferies on December 10, 2024, Initiated its previous ‘Buy’ rating for NEO. Craig Hallum also rated NEO shares as ‘Buy’, setting a target price of $26 on the company’s shares in an initiating report dated May 01, 2024. BTIG Research Reiterated the rating as Buy on December 29, 2023, but set its price target from $25 to $21. Stephens August 21, 2023d its ‘Equal-Weight’ rating to ‘Overweight’ for NEO, as published in its report on August 21, 2023. BTIG Research also rated the stock as ‘Buy’.
Analysis of Neogenomics Inc (NEO)
Further, the quarter-over-quarter increase in sales is 10.44%, showing a positive trend in the upcoming months.
Neogenomics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -8.38% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.91, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and NEO has an average volume of 779.05K. On a monthly basis, the volatility of the stock is set at 6.16%, whereas on a weekly basis, it is put at 12.63%, with a loss of -22.10% over the past seven days. Furthermore, long-term investors anticipate a median target price of $20.46, showing growth from the present price of $13.78, which can serve as yet another indication of whether NEO is worth investing in or should be passed over.
How Do You Analyze Neogenomics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.18%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 97.52% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NEO shares are owned by institutional investors to the tune of 97.52% at present.
